Stephanie Griffith-Richards

Dr. Stephanie Griffith-Richards


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2020 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
SMStephanus T. Malherbe
Stephanus T. Malherbe
RCRay Y. Chen
Ray Y. Chen
PDPatrick Dupont
Patrick Dupont
IKIlse Kant
Ilse Kant
MKMagdalena Kriel
Magdalena Kriel
GWGerhard Walzl
Gerhard Walzl
Background: There is a growing interest in the use of F-18 FDG PET-CT to monitor tuberculosis (TB) treatment response. Tuberculosis lung lesions are often complex and diffuse, with dynamic changes during treatment and persisting metabolic activity after apparent clinical cure. This poses a challenge in quantifying scan-based markers of burden of disease and disease activity. We used semi-automated, whole lung quantification of lung lesions to analyse serial FDG PET-CT scans from the Catalysis TB Treatment Response Cohort to identify characteristics that best correlated with clinical and microbiological outcomes. Results: Quantified scan metrics were already associated with clinical outcomes at diagnosis and 1 month after treatment, with further improved accuracy to differentiate clinical outcomes after standard treatment duration (month 6). A high cavity volume showed the strongest association with a risk of treatment failure (AUC 0.81 to predict failure at diagnosis), while a suboptimal reduction of the total glycolytic activity in lung lesions during treatment had the strongest association with recurrent disease (AUC 0.8 to predict pooled unfavourable outcomes). During the first year after TB treatment lesion burden reduced; but for many patients, there were continued dynamic changes of individual lesions. Conclusions: Quantification of FDG PET-CT images better characterised TB treatment outcomes than qualitative scan patterns and robustly measured the burden of disease. In future, validated metrics may be used to stratify patients and help evaluate the effectiveness of TB treatment modalities.

26 May 2007 in Pediatric Radiology
Verified
Journal Article
Closed access
PDF file
SGStephanie Griffith-Richards
Stephanie Griffith-Richards
PGPierre Goussard
Pierre Goussard
SASavvas Andronikou
Savvas Andronikou
RGRobert P. Gie
Robert P. Gie
SPStefan J. Przybojewski
Stefan J. Przybojewski
DKDavid L. Kathan
David L. Kathan

20 April 2021 in Cells
Verified
Journal Article
Open access
PDF file
LBLina Bergman
Lina Bergman
KBKarl Bergman
Karl Bergman
ELEduard Langenegger
Eduard Langenegger
AMAshley Moodley
Ashley Moodley
SGStephanie Griffith-Richards
Stephanie Griffith-Richards
CCCatherine Cluver
Catherine Cluver
Pre-eclampsia is a leading cause of maternal and perinatal morbidity and mortality. The burden of disease lies mainly in low-middle income countries. The aim of this project is to establish a pre-eclampsia biobank in South Africa to facilitate research in the field of pre-eclampsia with a focus on phenotyping severe disease.The approach of our biobank is to collect biological specimens, detailed clinical data, tests, and biophysical examinations, including magnetic resonance imaging (MRI) of the brain, MRI of the heart, transcranial Doppler, echocardiography, and cognitive function tests.Women diagnosed with pre-eclampsia and normotensive controls are enrolled in the biobank at admission to Tygerberg University Hospital (Cape Town, South Africa). Biological samples and clinical data are collected at inclusion/delivery and during the hospital stay. Special investigations as per above are performed in a subset of women. After two months, women are followed up by telephonic interviews. This project aims to establish a biobank and database for severe organ complications of pre-eclampsia in a low-middle income country where the incidence of pre-eclampsia with organ complications is high. The study integrates different methods to investigate pre-eclampsia, focusing on improved understanding of pathophysiology, prediction of organ complications, and potentially future drug evaluation and discovery.

25 June 2018 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
TCthe Catalysis Biomarker Consortium
the Catalysis Biomarker Consortium
SMStephanus T. Malherbe
Stephanus T. Malherbe
PDPatrick Dupont
Patrick Dupont
IKIlse Kant
Ilse Kant
PAPetri Ahlers
Petri Ahlers
JWJames M. Warwick
James M. Warwick
There is a growing interest in the use of 18F-FDG PET-CT to monitor tuberculosis (TB) treatment response. However, TB causes complex and widespread pathology, which is challenging to segment and quantify in a reproducible manner. To address this, we developed a technique to standardise uptake (Z-score), segment and quantify tuberculous lung lesions on PET and CT concurrently, in order to track changes over time. We used open source tools and created a MATLAB script. The technique was optimised on a training set of five pulmonary tuberculosis (PTB) cases after standard TB therapy and 15 control patients with lesion-free lungs. We compared the proposed method to a fixed threshold (SUV > 1) and manual segmentation by two readers and piloted the technique successfully on scans of five control patients and five PTB cases (four cured and one failed treatment case), at diagnosis and after 1 and 6 months of treatment. There was a better correlation between the Z-score-based segmentation and manual segmentation than SUV > 1 and manual segmentation in terms of overall spatial overlap (measured in Dice similarity coefficient) and specificity (1 minus false positive volume fraction). However, SUV > 1 segmentation appeared more sensitive. Both the Z-score and SUV > 1 showed very low variability when measuring change over time. In addition, total glycolytic activity, calculated using segmentation by Z-score and lesion-to-background ratio, correlated well with traditional total glycolytic activity calculations. The technique quantified various PET and CT parameters, including the total glycolytic activity index, metabolic lesion volume, lesion volumes at different CT densities and combined PET and CT parameters. The quantified metrics showed a marked decrease in the cured cases, with changes already apparent at month one, but remained largely unchanged in the failed treatment case. Our technique is promising to segment and quantify the lung scans of pulmonary tuberculosis patients in a semi-automatic manner, appropriate for measuring treatment response. Further validation is required in larger cohorts.

19 November 2019 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
CBC. Burger
C. Burger
JHJ. L. Holness
J. L. Holness
DSD. P. Smit
D. P. Smit
SGStephanie Griffith-Richards
Stephanie Griffith-Richards
CKC. F. N. Koegelenberg
C. F. N. Koegelenberg
AEA. Ellmann
A. Ellmann
Purpose: To determine the utility of fluorine-18 fluorodeoxyglucose Positron Emission Tomography Computed Tomography (FDG PET/CT) in patients with suspected ocular sarcoidosis (OS) or intraocular tuberculosis (IOTB) in a resource-constrained, TB endemic area. Methods: Independent review of the FDG PET/CTs, Computed Tomography (CT) scans and chest radiographs (CXRs) of patients with suspected OS or IOTB and inconclusive conventional workup. Results: Twenty-nine PET/CTs and CXRs were reviewed, with 38% of PET/CTs and CTs demonstrating evidence of TB or sarcoidosis, compared to 21% of CXRs. The sensitivity, specificity, positive and negative predictive values for PET/CT and CT were similar - 85.7%, 95.5%, 85.7% and 95.5% for OS, and 33.3%, 100%, 100% and 68% for IOTB respectively and for CXR, 57.1%, 100%, 100% and 88% for OS, and 16.7%, 100%, 100% and 63% for IOTB. Conclusion: PET/CT added no significant additional benefit over Chest CT in patients with suspected OS or IOTB.

1 July 2021 in Tuberculosis
Verified
Journal Article
Closed access
TMTheresa N. Mann
Theresa N. Mann
JWJames Warwick
James Warwick
NCNovel N Chegou
Novel N Chegou
JDJohan H. Davis
Johan H. Davis
CBCaroline G.G. Beltran
Caroline G.G. Beltran
GWGerhard Walzl
Gerhard Walzl